AUPH News and Press, Aurinia Pharmaceuticals Inc From 06/09/20

Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that additional safety data from the completed AURORA pivotal ...

- All pre-specified subgroup analyses in the pivotal trial favored voclosporin over placebo - Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin ...

A crucial aspect of success in investing in biotech stocks is that of timing. Buying a stock too early can mean enduring infinite dilution and clinical trial failures before a company can finally bring a product to market. On the other hand, buying a stock too late can mean missing out on the i...

Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the nine incumbent directors of the Company were elected at the Company’s annual general meeting held on June 2, 2020 (the “Meeting”...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at...

What investor doesn't want to own a solid company with exciting prospects for business growth in the near- and mid-term? Healthcare stocks often provide a safe haven during uncertain market conditions. Here we explore a few interesting opportunities ranging from a big pharma name to a pre-reve...

Aurinia Files Application for Voclosporin Approval Aurinia Pharmaceuticals Inc. ( AUPH ) announced that it has submitting a New Drug Application for voclosporin for treating kidney inflammation. The company submitted the data obtained from a global clinical program including the pivotal ...

Aurinia Pharmaceuticals (NASDAQ: AUPH ) has completed the rolling submission of a New Drug Application (“NDA”) to the FDA for voclosporin as a potential treatment for lupus nephritis (“LN”), a serious inflammation of the kidneys caused by the autoimmune disease ...

- Potential for voclosporin to become the first FDA-approved therapy for the treatment of lupus nephritis - - NDA Application supported by extensive global clinical program including the pivotal Phase 3 AURORA study and the pivotal Phase 2 AURA LV study - Aurinia Pharmaceuticals ...

Image source: The Motley Fool. Aurinia Pharmaceuticals Inc    (NASDAQ: AUPH) Q1 2020 Earnings Call May. 14, 2020 , 2:30 p.m. ET Operator Continue reading